BioSpace News Archive

CorVista Health, Inc, a digital health company dedicated to improving cardiovascular disease diagnosis, announces that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the CorVista System as a first non-invasive point of care diagnostic solution for patients with suspected pulmonary hypertension.

Merck will provide the investigational vaccine based on a proven platform technology.

Aravive, Inc. announced that it has entered into definitive agreements with new biotechnology investors, existing investors, Company management and Company Directors for the issuance and sale of an aggregate of 45,178,811 shares of its common stock.

Proteros biostructures GmbH announced that it has initiated a multi-target drug discovery partnership with Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases.

aTyr Pharma, Inc. announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the Jefferies London Healthcare Conference, which is scheduled to take place November 15 – 17, 2022, in London, U.K.

Oblato, Inc. a subsidiary company of HLB Therapeutics in Korea, announced that the enrollment of recurrent glioblastoma multiforme patients for a Phase 2 clinical trial with its proprietary compound OKN-007 in the US has been completed.

BerGenBio ASA and Meteva AS announced that they have entered into a shareholder loan facility, pursuant to which Meteva will make available to BerGenBio up to NOK 100 million.

avateramedical GmbH, an innovative German medical technology company specializing in robot-assisted, minimally invasive surgery, is pleased to announce that its avatera system, which is in clinical use at several clinics across Europe, has successfully completed its first live surgery during the annual meeting of the German Society for Robot-Assisted Urology.

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced that it has opened a new state-of-the-art facility in Granta Park, Cambridgeshire, UK, to support the Company’s growth.

Centene Corporation announced its financial results for the third quarter ended September 30, 2022.